- Austria / Österreich
- Bosnia and Herzegovina / Босна и Херцеговина
- Bulgaria / България
- Croatia / Hrvatska
- Czech Republic & Slovakia / Česká republika & Slovensko
- Finland / Suomi
- France / France
- Germany / Deutschland
- Greece / ΕΛΛΑΔΑ
- Italy / Italia
- Netherlands / Nederland
- Nordic / Nordic
- Poland / Polska
- Portugal / Portugal
- Romania & Moldova / România & Moldova
- Slovenia / Slovenija
- Serbia & Montenegro / Србија и Црна Гора
- Spain / España
- Switzerland / Schweiz
- Turkey / Türkiye
- UK & Ireland / UK & Ireland
An abnormal immune response or “feedback loop” could very well be the underlying cause of metastases in oral cancers, according to Dr. Marco Magalhaes, assistant professor at the University of Toronto’s Faculty of Dentistry and lead researcher in a study published in the journal Cancer Immunology Research. Magalhaes has unearthed a significant connection between the inflammatory response of a very specific form of immune cells, neutrophils, and the spread of this deadly disease.
“There’s a unique inflammatory response with oral cancers,” explains Magalhaes, citing the growing body of evidence between cellular inflammation and cancer, “because the oral cavity is quite unique in the body. A great many things are happening at the same time.”
Magalhaes focused attention on neutrophils, immune cells commonly found in saliva and the oral cavity but not widely researched in relation to oral cancer. Like other immune cells, neutrophils secrete a group of molecules, including TNFa, that regulates how the body responds to inflammation.
The study noted that oral cancer cells secreted IL8, another inflammatory mediator, which activates neutrophils, effectively establishing a massive immune-response buildup or “feedback loop.”
Ultimately, the researchers found, the immune-response loop resulted in increased invasive structures known as “invadapodia,” used by the cancer cells to invade and metastasize.
“If we understand how the immune system interacts with the cancer, we can modulate the immune response to acquire an anti-cancer response instead of a pro-tumor response,” Magalhaes argues.
While the study points to the possibility of one day creating targeted, personalized immunotherapies for patients with oral cancer that could effectively shut down the abnormal immune response, the team is currently expanding upon their study of inflammation and oral cancer.
Approximately 3,600 cases of oral cancer are diagnosed in Canada every year, yet the survival rates — 50 to 60 percent over five years — have remained stagnant for decades while other cancer survival rates have dramatically improved.
About the Faculty of Dentistry, University of Toronto
Combining the rigours of biological and clinical research with a comprehensive educational experience across a full range of undergraduate and graduate programs — with and without advanced specialty training — the Faculty of Dentistry at the University of Toronto has earned international respect for its dental research and training.
Whether focused on biomaterials and microbiology, next-generation nanoparticles, stem-cell therapies or ground-breaking population and access-to-care studies, the mission is to shape the future of dentistry and promote optimal health by striving for integrity and excellence in all aspects of research, education and clinical practice. You can learn more at www.dentistry.utoronto.ca.
(Source: University of Toronto)
Thu. 4 April 2024
4:00 PM EST (Toronto)
Reimagining success with ClearCorrect: From case planning to practice growth
Tue. 9 April 2024
1:00 PM EST (Toronto)
Soluzioni innovative per sostenere l’evoluzione dello studio: Lo strumento giusto può fare la differenza
Tue. 9 April 2024
7:00 PM EST (Toronto)
ITI US section live treatment planning session
Wed. 10 April 2024
5:00 AM EST (Toronto)
A tooth is extracted—what now? Is there any benefit to ridge augmentation?
Wed. 10 April 2024
8:00 PM EST (Toronto)
Santa Fe Group Medicare Update
Thu. 11 April 2024
3:30 AM EST (Toronto)
Por qué implementar Invisalign Go en tu consulta?
Mon. 15 April 2024
4:00 PM EST (Toronto)
To post a reply please login or register